Kornimate/medical-research-clean huggingface dataset:
surgery with or without hepatic arterial chemotherapy in treating patients with liver cancer

Conditions: Localized Resectable Adult Primary Liver Cancer; Stage III Childhood Liver Cancer

Summary: rationale: drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. giving drugs directly into the arteries around the tumor may kill more tumor cells. giving chemotherapy after surgery may kill any remaining tumor cells. it is not yet known whether surgery and hepatic arterial chemotherapy are more effective than surgery alone in treating patients with liver cancer that has spread to the portal vein. purpose: this randomized phase iii trial is studying surgery and hepatic arterial chemotherapy to see how well they work compared to surgery alone in treating patients with liver cancer that has spread to the portal vein.

objectives: * compare the efficacy of surgical resection with vs without postoperative hepatic arterial chemotherapy in patients with hepatocellular carcinoma and portal vein tumor thrombus. outline: this is a randomized, multicenter study. patients are stratified according to grade of portal invasion and child-pugh classification. patients are randomized to 1 of 2 treatment arms. * arm i: patients undergo macroscopic curative resection. within 28 days after surgery, patients without post-surgery complications undergo hepatic arterial infusion comprising fluorouracil and cisplatin on days 1-5, 8-12, and 15-19. treatment continues for 6 months. * arm ii: patients undergo macroscopic curative resection. projected accrual: a total of 100 patients (50 per treatment arm) will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed hepatocellular carcinoma (hcc) with portal vein tumor thrombus * tumor thrombus in the main trunk or first branch of the portal vein * no apparent distant metastases on chest ct scan and bone scintigraphy within the past 6 weeks * no pleural effusion or ascites patient characteristics: age * not specified performance status * ecog 0-1 life expectancy * not specified hematopoietic * neutrophil count \> 1,000/mm\^3 * platelet count \> 50,000/mm\^3 * hemoglobin \> 8 g/dl hepatic * bilirubin \< 2 times upper limit of normal (uln) * alt and ast \< 4 times uln renal * creatinine normal cardiovascular * no severe heart disease * no cardiac effusion other * no other malignant disease * no high risk for esophageal varices rupture * no allergy to fluorouracil or cisplatin prior concurrent therapy: biologic therapy * not specified chemotherapy * no prior hepatic arterial chemotherapy * no prior systemic chemotherapy for hcc endocrine therapy * not specified radiotherapy * not specified surgery * not specified
comparison of cervical region characteristics of people with smartphone addiction

Conditions: Neck Pain; Postural; Defect; Young Adult; Technology

Summary: in healthy participantsng adults, the anterior tilt position of the head and consequently flattening of the cervical lordosis may results in impaired neutral posture of the spine during daily long-term computer etc. use with today's technology. in addition, the increasing use of smart phones may also promote this negative results. according to a study, the estimated total smartphone sales for 2012 was 660 million, but as of 2015, it is estimated that a total of one billion units worldwide. it is also thought that phone sales will continue to increase over the years, as it facilitates daily life activities. as a result of our literature review, the investigators have not come across a study that evaluates demographic information such as the duration of using smartphones or computers, cervical position sense, neck muscle strength, physical activity and general psychological status, which the investigators think may affect the performance of deep cervical flexor muscles in healthy participantsng adults. with this study, it will be ensured that more information about the factors affecting the performance of deep cervical flexor muscles will be determined in advance and necessary steps will be taken to prevent the factors that may cause neck problems in the future.


Eligibility criteria:
inclusion criteria: * being in the age range of 18-30, * not having mental - cognitive problems, * being a volunteer participant. exclusion criteria: * having any surgery on the vertebral column, * having an inflammatory disease, * having a rheumatological disease, * having a history of malignancy, * having congenital spinal cord anomalies, congenital and / or subsequent spinal deformities, * having radiculopathy, myelopathy and / or other neurological disorders, vestibular disorders, * having a history of acute trauma.
evaluation of the scar healing effects of chitocare medical scar healing gel in women undergoing breast reduction or mastopexy surgery (chitoscar)

Conditions: Surgical Scars

Summary: patients undergoing breast reduction or mastopexy surgery will be screened and recruited for participation in the study. eligible patients will act as their own control with one breast receiving the active intervention (chitocare® medical scar healing gel) and the other receiving standard of care (amoena curascar mammilla circles silicone scar patch and amoena curascar anchors silicone scar patch). the active and control interventions will be applied for six months, and participants will be followed for up to 12 months. the scar properties of each breast will be assessed at study initiation (day 0) and at study visits at 3, 6, 9, and 12 months using the patient and observer scar assessment scale (posas) and via blinded assessment of photographs. other subjective parameters such as pain, itching, and overall perception of the healed wound will be collected at each study visit via the posas, and patients' opinion, preferences, and compliance regarding the treatments will be collected via a basic questionnaire.


Eligibility criteria:
inclusion criteria: * written informed consent must be given * female ≥ 18 years old * having planned or very recently (within 21 days) undergone breast reduction or mastopexy surgery on both breasts * not yet begun any treatment aimed at reducing scarring * wound is not infected at the time of enrolment * able to understand and comply with the requirements of the study exclusion criteria: * patients with serious concomitant disease (cancer, heart failure (nyha class iv), severe anaemia (hb\<100 g/l), neoplasia) * any significant condition that may preclude the participant from the study (e.g. severe depression or psychiatric illness) * patients who will require additional surgical procedures during the study * patients diagnosed with autoimmune connective tissue diseases * previous treatment under this clinical protocol * participation in another clinical trial * receiving or scheduled to receive a medication or treatment which, in the opinion of the investigator, is known to interfere with, or affect the rate and quality of wound healing * allergy to shellfish\* (if unknown, the patient may try a small sample of the ip on their intact skin to assess for any potential allergic reaction.) * medical condition likely to require systemic corticosteroids during the study period * pregnant or lactating women * smoker
study of roxadustat for reducing the incidence of acute kidney injury after coronary artery bypass grafting

Conditions: Coronary Artery Bypass

Summary: acute kidney injury is a frequent complication after coronary artery bypass grafting (cabg). roxadustat is a prolyl hydroxylase inhibitor (phi) which can stabilize hypoxia-inducible factor (hif) and improve the hypoxic tolerance of tissues. roxadustat has shown effect in reducing acute kidney injury in animal studies. this study aims to evaluate the efficacy of administration of roxadustat before surgery in the prevention of acute kidney injury after cabg.

acute kidney injury is a frequent complication after coronary artery bypass grafting (cabg), with a incidence of 28-38%. renal ischemia-reperfusion injury is the main mechanism for acute kidney injury after cabg. roxadustat is a kind of prolyl hydroxylase inhibitor (phi) which can stabilize hypoxia-inducible factor (hif) and improve the hypoxic tolerance of tissues. roxadustat has shown effect in reducing acute kidney injury in animal studies. this study aims to evaluate the efficacy of administration of roxadustat (before surgery) in the prevention of acute kidney injury after cabg. this is a multicenter, randomized, double-blind, placebo-controlled study.

Eligibility criteria:
inclusion criteria: * 18-80 years old * non-emergent cabg and planned cardiopulmonary bypass (cpb) * egfr\>15ml/min/1.73m2 exclusion criteria: * pregnancy or breast feeding * malignancy * severe liver dysfunction * acute kidney injury before randomization * uncontrolled hypertension

Keywords: acute kidney injury coronary artery bypass roxadustat
improving medication adherence in post-acs patients

Conditions: Medication Adherence; Acute Coronary Syndrome

Summary: many post acute coronary syndrome(acs) patients do not take their medications (including aspirin) as prescribed, leading to an increase in mortality. patients enrolled in this study will be enrolled into one of two groups. patients in the first group will have their medication adherence measured, but will receive all other care as usual. patients in the second group will also have their medication adherence measured, but they will receive telephone-delivered problem solving therapy (pst) in addition to their usual care. the two groups will be combined to determine the minimally effective dose (med) and the maximally tolerated dose (mtd) for adherence to aspirin. the medication adherence of the pst group will improve by 20% (\ 75%).


Eligibility criteria:
inclusion criteria: 1. medical eligibility: 1. patient presenting for staged intervention with positive cardiac history or 2. patient with stable cad who received cardiac admission but does not report chest pain. or 3. patient with stable cad who has had a cardiac admission in the past. 2. patient is non-adherent to prescribed medication. the following exclusion criteria have been set for either safety concerns or concerns that patients will not be able to complete the protocol: 1. inability to communicate in english or spanish 2. unwilling to be randomized or to have aspirin in a separate bottle if they use a pill box 3. unavailability for the 1 month period of the study (including being unavailable by phone and/or traveling out of the country) 4. medically unable to receive aspirin (e.g. allergy, contra-indicated, etc) 5. deemed unable to comply with the protocol (either self selected or by indicating during screening that s/he could not complete all requested tasks). this includes patients with a level of cognitive impairment indicative of dementia, and patients with current alcohol or substance abuse. 6. deemed to need immediate psychiatric assessment (e.g., must be hospitalized, or have some other psychiatric intervention conducted within 72 hours). 7. active psychosis, bipolar disorder, or any overt personality disorder

Keywords: medication adherence
perceptions and representations of cancer chemotherapy

Conditions: Lung Cancer

Summary: qualitative study on data from interviews such patients, relatives and doctors involved in the implementation of cancer care. framework type of method using grounded theory

the word chemotherapy itself, because it belongs to the secular knowledge and therefore doxa is a hard word, which stores what it is stable, common and therefore impersonal. it has the properties of a symbol, that is to say that joint several meanings, some of which are contradictory. the objective of the research: to determine the perceptions and representations of chemotherapy, its physical impacts, psychological and relational. to qualitatively compare the performances of chemotherapy as it has an end as scheduled for adjuvant chemotherapy, or endless precise as in the palliative chemotherapy

Eligibility criteria:
inclusion criteria: * 30 major patients with lung cancer requiring chemotherapy either as palliative or adjuvant as surgical treatment * 30 significant others (relatives) major applicant lung cancer patients chemotherapy either palliation or as adjuvant to surgery * 15 doctors oncologists performing either chemotherapy as palliative or adjuvant as surgical treatment exclusion criteria: * na
brexpiprazole as an adjunctive treatment to paroxetine or sertraline in adult patients suffering from post-traumatic stress disorder (ptsd)

Conditions: Post-traumatic Stress Disorder; PTSD

Summary: to evaluate the efficacy of brexpiprazole as adjunctive treatment to paroxetine (par) or sertraline (ser) on ptsd symptoms.


Eligibility criteria:
inclusion criteria: * the patient has ptsd, diagnosed according to dsm-iv-tr™ and confirmed by the mini international neuropsychiatric interview (mini). * the patient has a clinician-administered ptsd scale part 2 (caps-2) total score ≥70 at screening and baseline visits. * the reported duration of the ptsd is at least 3 months. exclusion criteria: * the index traumatic event that led to development of ptsd took place more than 15 years before screening. * the patient has a severe personality disorder that in the investigator's opinion may interfere with the conduct of the study. * the patient is at significant suicidal risk. other inclusion and exclusion criteria may apply.
release of epoxyeicosatrienoic acids from erythrocytes during the use of extracorporeal procedures (heart-lung machine)

Conditions: Coronary Arteriosclerosis; Valve Heart Disease

Summary: hypotension with potentially serious consequences for organ perfusion is a common complication in extracorporeal procedures such as heart-lung-machine. the exact reasons for this are still insufficiently clarified. probably periinterventional vasorelaxant released substances play a crucial role in these procedures. these substances could be due to contact of blood cells with the membrane in the hlm arise. in this project the hypothesis will be checked, if eets / dhets are released by erythrocytes during this extracorporeal procedure and thus act as potential candidate products for the result of hypotonic phases during usage of heart-lung-machine. we will determine differences in rbc fatty acids profiling in patients before and after heart-lung-machine intervention. rbc fatty acids profiling will be achieved by using targeted hplc-ms mass spectrometry. it is believed that during hlm there is an increase in eets / dhets in the serum and in the erythrocytes. it is believed that shear forces play an important role in the release of erythrocyte eets / dhets.


Eligibility criteria:
inclusion criteria: * patients who are undergoing an operation with the aid of the heart-lung machine for cardiac surgery * age over 18 years * ability to consent * there is a written consent of the study participant exclusion criteria: •none

Keywords: fatty acid metabolism erythrocytes lipidomics heart-lung-machine
erector spinae plane block after lumbar spinal stenosis surgery

Conditions: Lumbar Spinal Stenosis; Erector Spinae Plane Block

Summary: lumbar spinae stenosis surgery is a frequent intervention resulting in important postoperative pain. management of this postoperative pain is thus important. different pain management therapies exist. the erector spinae plane (esp) block was described in 2016. it involves the injection of local anesthetics into the interfascial plane, deep to erector spinae muscle, allowing the blockade of the dorsal and ventral rami of the thoracic spinal nerves. it was initially proposed for analgesia of costal fractures, pulmonary lobectomy and thoracic vertebrae. the esp block (espb) could probably be extended to a large number of surgical procedures. espb has so far not been investigated in lumbar spinae stenosis surgery.


Eligibility criteria:
inclusion criteria: - any lumbar spinae surgery on 2 or more lumbar levels exclusion criteria: * contraindication to nsaid * allergy to any local anesthetics
comparison of effectiveness of topical retinoids versus liquid nitrogen in treatment of plantar warts(viral infection)

Conditions: Viral Warts

Summary: this is a comparative study between two treatment options for skin viral infection.

this is a comparative study between two treatment for viral infection in epidermal layer of skin that proliferates slowly forming thick, growths. this study will compare and evaluate the differences in efficacy between topical liquid nitrogen and topical retinoids.

Eligibility criteria:
inclusion criteria: - patients age limit 18-60 years patients with either gender (male/female) patients with recurrent plantar warts exclusion criteria: * pregnancy/lactation. pt on topical or systemic therapy in last 6 months. on immunosuppressants. \> 5 lesions. pts with local secondary infections.

Keywords: plantar warts topical adapalene gel cryotherapy
a study to evaluate intramuscular asp7374

Conditions: Influenza; Vaccine

Summary: the purpose of this study is to evaluate safety and immunogenicity of intramuscular asp7374 in adults ≥61 years of age.


Eligibility criteria:
inclusion criteria: * healthy or medically stable, as judged on the basis of history and concurrent diseases. * subject understands procedure of the protocol and is willing to comply with the protocol. * written informed consent has been obtained. exclusion criteria: * scheduled to receive another vaccine during the study. * received influenza ha vaccine within 180 days prior to screening. * received or scheduled to receive a live vaccine within 28 days prior to vaccination with the study vaccine, and received or scheduled to receive an inactivated vaccine or a toxoid within 7 days prior to vaccination with the study vaccine. * diagnosis of immune deficit in the past, has a family member (within the third degree of kinship) with a diagnosis of congenital immunodeficiency syndrome. * received one of the following medications or treatment prior to vaccination with the study vaccine: interferon formulation, drugs which affect the immune system, corticosteroids, g-csf, m-csf, human immunoglobulin products, blood products, blood transfusion * history of anaphylactic shock or an allergic reaction such as generalized eruption due to food or drug (including vaccines) allergies, fever ≥39.0°c within 2 days after the previous vaccination (influenza vaccine and others) * history of seizures, except for febrile seizures in childhood

Keywords: asp7374 prevention of seasonal influenza
effects of cbt-based intervention among patients with liver cancer

Conditions: Depression; Anxiety; Liver Cancer; CBT

Summary: this study investigates the effects of a cbt- based intervention on depression, anxiety, immune function, quality of life, and overall survival. it also explores if the effects of the intervention on immune function and quality of life are mediated through the improvements in depression and anxiety among patients with liver cancer.

in the present research project, the investigators have developed a cognitive behavioral therapy (cbt)-based intervention protocol to investigate the impact of this intervention on depression, anxiety, quality of life, immune function, and overall survival in patients diagnosed with liver cancer. additionally, this research protocol aims to examine the hypothesized mechanisms underlying the effects of the cbt-based intervention on quality of life and immune function. specifically, we will investigate: 1) whether the effect of the cbt-based intervention on quality of life is mediated by improvements in anxiety and depression, and 2) whether the effect of the cbt-based intervention on immune function is mediated by improvements in anxiety and depression among patients with liver cancer. a total of 160 participants will be recruited and randomly assigned to either the cbt-based intervention group or an educational group receiving non-psychological interventions. assessments will be conducted at baseline (pre-treatment) and at 3, 6, and 12 months after the intervention period. survival data will be collected throughout the follow-up period until the patients' end-of-life. by examining the effects of the cbt-based intervention on multiple outcomes and exploring the potential mediating mechanisms, this research project aims to contribute to a comprehensive understanding of the intervention's effectiveness and its impact on the well-being of liver cancer patients.

Eligibility criteria:
inclusion criteria: 1. adults (aged ≥18); 2. diagnosed with liver cancer based on pathological findings or imaging findings in the medical record; 3. the severity level of depression and anxiety: depression \> 7 using had-d, or anxiety \> 7 using had-a (hospital anxiety and depression scale, hads; had-d, hospital depression scale; had-a, hospital anxiety scale). exclusion criteria: 1. patients who are taking part in another psychological intervention clinical trial or consented to receive another psychotherapy, suffered from aphasia and other communication difficulties will be excluded from the study 2. patients with active immunological diseases, such as autoimmune diseases, and inflammatory diseases. 3. patients accepting hormone therapy or taking long-term antibiotic drugs. 4. patients who lack the basic ability of understanding and expression and are incompetent in giving consent.

Keywords: cognitive behavioural therapy depression anxiety immune quality of life survival liver cancer
a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of certolizumab pegol in combination with methotrexate in the treatment of disease modifying antirheumatic drugs (dmard)-naïve adults with early active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: this study is intended to evaluate the efficacy and safety of certolizumab pegol (czp) in combination with methotrexate (mtx) for inducing and sustaining clinical response in the treatment of disease modifying antirheumatic drug (dmard)-naïve adults with early active rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * subjects must have a time since diagnosis of adult-onset rheumatoid arthritis (ra) less than 1 year as defined by the 2010 acr/eular classification criteria from screening visit * positive rheumatoid factor (rf) and/or positive anticyclic citrullinated peptide antibody (anti-ccp) * active ra disease * dmard-naïve * subject is naïve to ra related biologics exclusion criteria: * a diagnosis of any other inflammatory arthritis * history of infected joint prosthesis, or other significant infection and other serious medical condition * known tuberculosis (tb) disease or high risk of acquiring tb infection

Keywords: certolizumab pegol - cimzia methotrexate rheumatoid arthritis